News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,431 Results
Type
Article (45584)
Company Profile (336)
Press Release (657511)
Section
Business (208663)
Career Advice (2207)
Deals (36218)
Drug Delivery (93)
Drug Development (82312)
Employer Resources (173)
FDA (16233)
Job Trends (15188)
News (352177)
Policy (33119)
Tag
Academia (2568)
Alliances (50581)
Alzheimer's disease (1230)
Approvals (16145)
Artificial intelligence (118)
Bankruptcy (362)
Best Places to Work (11554)
Biotechnology (244)
Breast cancer (102)
Cancer (897)
Cardiovascular disease (79)
Career advice (1831)
Cell therapy (207)
Clinical research (65004)
Collaboration (332)
Compensation (156)
COVID-19 (2568)
Cystic fibrosis (80)
Data (833)
Diabetes (127)
Diagnostics (6156)
Drug pricing (81)
Earnings (84927)
Employer resources (151)
Events (112489)
Executive appointments (245)
FDA (16657)
Funding (291)
Gene therapy (156)
GLP-1 (583)
Government (4364)
Healthcare (18784)
Infectious disease (2642)
Inflammatory bowel disease (108)
Interviews (351)
IPO (16572)
Job creations (3922)
Job search strategy (1582)
Layoffs (422)
Legal (8049)
Lung cancer (153)
Manufacturing (159)
Medical device (13184)
Medtech (13189)
Mergers & acquisitions (19640)
Metabolic disorders (364)
Neuroscience (1476)
NextGen Class of 2024 (6652)
Non-profit (4509)
Northern California (1180)
Obesity (216)
Opinion (217)
Patents (96)
People (57776)
Phase I (20270)
Phase II (28675)
Phase III (21277)
Pipeline (202)
Postmarket research (2575)
Preclinical (8615)
Radiopharmaceuticals (237)
Rare diseases (188)
Real estate (6244)
Regulatory (21888)
Research institute (2363)
Resumes & cover letters (375)
Southern California (1064)
Startups (3816)
United States (11576)
Vaccines (558)
Weight loss (169)
Date
Today (180)
Last 7 days (842)
Last 30 days (2946)
Last 365 days (36796)
2024 (30668)
2023 (40710)
2022 (51903)
2021 (56380)
2020 (54703)
2019 (47162)
2018 (35604)
2017 (33154)
2016 (32601)
2015 (38467)
2014 (33847)
2013 (28964)
2012 (29451)
2011 (30121)
2010 (28200)
Location
Africa (796)
Arizona (189)
Asia (38995)
Australia (6536)
California (2692)
Canada (1159)
China (211)
Colorado (114)
Connecticut (117)
Europe (84763)
Florida (381)
Georgia (96)
Illinois (332)
Indiana (179)
Kansas (99)
Maryland (515)
Massachusetts (2193)
Michigan (143)
Minnesota (257)
New Jersey (820)
New York (819)
North Carolina (685)
Northern California (1180)
Ohio (124)
Pennsylvania (742)
South America (1185)
Southern California (1064)
Texas (374)
Washington State (319)
703,431 Results for "oncolytics biotech inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
Oncolytics Biotech ® Inc. today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics’ Board of Directors, will serve as the interim CEO during Dr. Coffey’s absence.
June 24, 2024
·
5 min read
Biotech Beach
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Oncolytics Biotech ® Inc. announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients.
June 20, 2024
·
9 min read
Policy
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
Oncolytics Biotech® Inc. announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration, supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer.
June 27, 2024
·
6 min read
Business
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Oncolytics Biotech today announced that it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR).
May 15, 2024
·
8 min read
Biotech Beach
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
Oncolytics Biotech® Inc., a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical Oncology Annual Meeting.
May 24, 2024
·
10 min read
Business
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
Oncolytics Biotech® Inc., a leading clinical-stage company specializing in immunotherapy for oncology, announced recent operational highlights and financial results for the first quarter ended March 31, 2024.
May 9, 2024
·
15 min read
Deals
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders - May 16, 2024
Oncolytics Biotech ® Inc. today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday, May 15, 2024.
May 16, 2024
·
2 min read
Business
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights - April 30, 2024
Oncolytics Biotech ® Inc. today announced that it will host a conference call and webcast on Thursday, May 9, 2024.
April 30, 2024
·
2 min read
Biotech Beach
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech ® Inc. today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 31 – June 4, 2024.
April 25, 2024
·
2 min read
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Oncolytics Biotech® Inc., a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals.
May 9, 2024
·
10 min read
1 of 70,344
Next
